HEOR Staff Writer

Ravulizumab aHUS Reimbursement Reassessment: Navigating New Evidence and Trea...
UK Risks Underestimating Life Sciences Investment Potential
Mounjaro Price Increase UK: Impacts on Access and Health Economics
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient...
EFPIA Response to Tariffs: Concerns Over U.S.-EU Trade Agreement Impact on Ph...